Introduction
Alzheimer's disease (AD) is the most frequent cause of dementia, which is characterized clinically by a progressive cognitive decline eventually resulting in death, usually within 10 years of diagnosis. Although there have been numerous advances in treatment options currently there are no effective treatments that can halt or reverse AD.
The neuropathological features of AD include neurofibrillary tangles (NFT), deposition of Aβ soluble (monomeric, oligomeric) and insoluble (senile plaques) forms, and neuronal loss in affected brain regions (Price and Sisodia, 1994) . During the last decade, much effort has been done on targeting clearance of Aβ from the brain of AD patients via the administration of anti-Aβ antibodies (passive vaccination) or Aβ antigens (active vaccination). While several clinical trials using active vaccines based on small B cell epitope of Aβ are ongoing, two major clinical trials on passive vaccination performed in patients with mild to moderate AD have been completed. Based on data from these passive vaccination trials, the scientific community and medical doctors have suggested that treatment must be initiated earlier on, at the prodromal stage, or even earlier. We assume that active immunization is the most feasible approach for the prevention or treatment at the early stage AD, if candidate vaccines are safe, fairly immunogenic in the elderly, and does not activate the potentially harmful autoreactive Th cells in vaccinated subjects. Previously, we reported on an AD epitope vaccines based on the conventional influenza vaccine (Davtyan et al., 2011) . Specifically, two chimeric flu viruses expressing either 7 or 10 aa of Aβ 42 (WSN-Aβ 1-7 or WSN-Aβ 1-10 ) were generated and tested in mice as inactivated vaccines. We demonstrated that this dual vaccine induced therapeutically potent anti-Aβ antibodies and anti-influenza antibodies in mice. This strategy might be beneficial for treatment of AD patients as well as for prevention of development of AD pathology in pre-symptomatic individuals while concurrently boosting immunity against influenza.
It is well known that although yearly influenza vaccines are different due to genetic drift in circulating viruses, they are conserved T and B cell antigenic epitopes in these vaccines. Specifically, the population of conserved memory CD4 + Th cells generated by vaccination and/or previous infection can be boosted by next year vaccination. Based on these observations, as well as on the results generated with other chimeric viruses (Gonzalo et al., 1999; Zheng et al., 2000) , including our AD epitope influenza vaccine results (Davtyan et al., 2013) we investigated whether pre-existing memory CD4 + T cells generated by influenza virus vaccination could impact the induction of anti-Aβ antibodies by B cells after Journal of Neuroimmunology 277 (2014) 77-84 
